Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Fiduciary Trust Co

Fiduciary Trust Co trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,206 shares of the biopharmaceutical company’s stock after selling 316 shares during the quarter. Fiduciary Trust Co’s holdings in Regeneron Pharmaceuticals were worth $5,846,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Capital International Investors raised its position in Regeneron Pharmaceuticals by 41.6% in the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock valued at $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after buying an additional 155,369 shares in the last quarter. Dodge & Cox raised its position in Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock worth $1,653,543,000 after acquiring an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 63.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after buying an additional 810,144 shares during the period. Finally, Franklin Resources Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 7.9% during the 4th quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock worth $1,456,864,000 after acquiring an additional 149,124 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. Robert W. Baird lowered their target price on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a “neutral” rating on the stock in a report on Friday, April 25th. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $695.00 price target for the company. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $762.00 to $834.00 in a research note on Wednesday, February 5th. Finally, TD Cowen decreased their target price on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $892.60.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $527.78 on Friday. The firm has a market capitalization of $57.70 billion, a PE ratio of 13.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. The firm has a fifty day simple moving average of $613.08 and a two-hundred day simple moving average of $696.77. Regeneron Pharmaceuticals, Inc. has a 12 month low of $520.50 and a 12 month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. During the same quarter in the prior year, the firm posted $9.55 earnings per share. The company’s revenue was down 3.7% on a year-over-year basis. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.67%. Regeneron Pharmaceuticals’s payout ratio is 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.